BioCryst receives early termination of Hart-Scott-Rodino waiting period for Astria acquisition.

Wednesday, Dec 3, 2025 7:08 am ET1min read
ATXS--
BCRX--

BioCryst Pharmaceuticals has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Astria Therapeutics. The merger is expected to close in Q1 2026, subject to customary closing conditions. BioCryst is a global biotechnology company focused on developing medicines for hereditary angioedema and other rare diseases.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet